Showing 91-100 of 119 results for "".
- JW Pharmaceutical Signs Global Out-licensing Agreement for Atopic Dermatitis Drug Candidate with LEO Pharmahttps://practicaldermatology.com/news/jw-pharmaceutical-signs-global-out-licensing-agreement-for-atopic-dermatitis-drug-candidate-with-leo-pharma/2457626/JW Pharmaceutical and LEO Pharma A/S have signed a global licensing agreement for JWP’s novel atopic dermatitis drug candidate, JW1601, under which, LEO Pharma will gain the exclusive rights to develop and commercialize JW1601 globally excluding Korea where JWP will maintain its exclusivity. JWP wi…
- Researchers Identify Cause of Aggressive SCCs in Recessive Dystrophic Epidermolysis Bullosahttps://practicaldermatology.com/news/researchers-identify-cause-of-aggressive-sccs-in-recessive-dystrophic-epidermolysis-bullosa/2457636/Immune system-related enzymes contribute significantly to the development of aggressive and fatal squamous cell carcinomas early in the life of individuals with recessive dystrophic epidermolysis bullosa (RDEB), an international team of scientists led by researchers at the Sidney Kimmel Cancer Cent…
- Escalier Biosciences' Doses First PsO Patient with ESR-114; Announces Clinical Advisory Boardhttps://practicaldermatology.com/news/escalier-biosciences-doses-first-patient-with-esr-114-announces-clinical-advisory-board/2457652/The first patient has been dosed in a Phase 1/2a study evaluating Escalier Biosciences’ ESR-114 topical gel for mild-to-moderate psoriasis. "The initiation of this study represents a significant milestone for Escalier as it validates our model of advancing high quality drug candidates from the ben…
- Dermatology Authority Adds Credentialing and Licensing Support Serviceshttps://practicaldermatology.com/news/dermatology-authority-adds-credentialing-and-licensing-support-services/2457711/Dermatology Authority has added credentialing and licensing to their list of support services. The requirements for licensing and credentialing differ from city to city, state to state, and procedure to procedure. Dermatology Authority keeps tabs on the requirements and agencies that license and cr…
- Encore Dermatology Launches Impoyz Cream 0.025%, a Newly Formulated High-Potency Topical Corticosteroidhttps://practicaldermatology.com/news/encore-dermatology-launches-impoyz-cream-0025-a-newly-formulated-high-potency-topical-corticosteroid/2457787/Encore Dermatology Inc. launched its new topical product, Impoyz Cream, indicated for the treatment of moderate to severe plaque psoriasis in patients 18 years of age or older. Impoyz Cream is the only FDA-approved high-potency topical corticosteroid with 0.025% clobetasol propionate. “Psoriasis p…
- Desmoplastic Melanoma May Be Highly Responsive to Anti-PD-1/PD-L1 Therapieshttps://practicaldermatology.com/news/desmoplastic-melanoma-may-be-highly-responsive-to-anti-pd-1pd-l1-therapies/2457926/Patients with desmoplastic melanoma are more responsive to immune-activating anti-PD-1/PD-L1 therapies than previously assumed, Moffitt Cancer Center researchers report in the Jan. 10 issue of Nature. Pembrolizumab and nivolumab have been approved to treat melanoma, and these drugs block the inter…
- Gene Expressions May Be Key to More Youthful Looking Skinhttps://practicaldermatology.com/news/gene-expressions-may-be-key-to-more-youthful-looking-skin/2457962/Some individuals’ skin appears more youthful than their chronologic age, and now new research indicates that increased expression of certain genes may be the key to intrinsically younger looking — and younger behaving — skin. The findings appear in the Journal of the American Academy of Dermatolog…
- Tildrakizumab Performs Well in Two Phase 3 Psoriasis Studieshttps://practicaldermatology.com/news/tildrakizumab-performs-well-in-two-phase-3-psoriasis-studies/2458164/Two Phase 3 trials show that tildrakizumab is efficacious and well-tolerated in patients with moderate-to-severe chronic plaque psoriasis. Specifically more than 60 percent of all patients who received the active medication showed improvement, compared to less than 10 percent of patients who recei…
- Is Widespread Vitamin D Deficiency Due to Chronic Disease, Sunscreen Use? New Study Says Yeshttps://practicaldermatology.com/news/is-widespread-vitamin-d-deficiency-due-to-chronic-disease-sunscreen-use-new-study-says-yes/2458205/Nearly 1 billion people worldwide may have deficient or insufficient levels of vitamin D due to chronic disease and inadequate sun exposure related to sunscreen use, according to a study in the Journal of the American Osteopathic Association. The study also found that 95 percent of African America…
- Congratulations: American Skin Association Announces 2017 Research Scholar Awards and Research Grantshttps://practicaldermatology.com/news/congratulations-american-skin-association-announces-2017-research-scholar-awards-and-research-grants/2458307/And the winners are … The American Skin Association (ASA) research scholar awards and research grants are: ASA Carson Research Scholar Award in Psoriasis Cory L. Simpson, MD, PhD University of Pennsylvania Role of Autophagy in Psoriasis Pathogenesis ASA Milstein Research Scholar Awards in Melan…